Alpha Cognition Stock Quote ACOG - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

5.47

Bid

4.50

Ask

8.69

Volume

0.00 Day's Range 0.00

4.66 52 Week Range 7.00

Previous Close

5.47

Open

Last Trade

Last Trade Time

Average Volume (3m)

91,086

Financial Volume

VWAP

FeaturedNorthstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Form 8-K - Current report

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for...

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated financial markets for 12,000 U.S. and...

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies...

Form POS AM - Post-Effective amendments for registration statement

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating...

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies...

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.23	-4.0350877193	5.7	6	4.89	25488	5.47689013	CS
4	-0.56	-9.28689883914	6.03	6.88	4.89	56952	6.05089061	CS
12	0.4042	7.97899640728	5.0658	7	4.81	91086	5.91019181	CS
26	-1.53	-21.8571428571	7	7	4.66	102013	5.88264726	CS
52	-1.53	-21.8571428571	7	7	4.66	102013	5.88264726	CS
156	-1.53	-21.8571428571	7	7	4.66	102013	5.88264726	CS
260	-1.53	-21.8571428571	7	7	4.66	102013	5.88264726	CS

ACOG - Frequently Asked Questions (FAQ)

What is the current Alpha Cognition share price?

The current share price of Alpha Cognition is $ 5.47

What is the 1 year trading range for Alpha Cognition share price?

Alpha Cognition has traded in the range of $ 4.66 to $ 7.00 during the past year

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TSVT2seventy bio Inc	$ 4.915 (75.54%)	300.47k
TNONTenon Medical Inc	$ 2.06 (64.80%)	5.08M
TILEInterface Inc	$ 28.00 (49.73%)	262
AWHAspira Womans Health Inc	$ 0.2944 (48.69%)	9.47M
ADTNADTRAN Holdings Inc	$ 11.49 (35.34%)	3
PHATPhathom Pharmaceuticals Inc	$ 2.00 (-54.55%)	105
NEOGNeogen Corporation	$ 6.03 (-39.58%)	8
JANXJanux Therapeutics Inc	$ 20.05 (-33.65%)	13
LZMHLZ Technology Holdings Ltd	$ 12.01 (-23.31%)	7
SNCRSynchronoss Technologies Inc	$ 6.01 (-22.45%)	3
AWHAspira Womans Health Inc	$ 0.2934 (48.18%)	9.49M
BTOGBit Origin Ltd	$ 0.5402 (13.70%)	7.84M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 7.87 (6.64%)	7.06M
CUTRCutera Inc	$ 0.1661 (29.26%)	5.54M
TNONTenon Medical Inc	$ 2.06 (64.80%)	5.08M

QaB2i 3 minutes ago

Fresh battery's and a latte - ready !

TWOH

Diego Rivas 3 minutes ago

Does anyone have any insight on this. I think maybe we could double bottom here and have some nice days

OCEA

amelia43 4 minutes ago

Which one? The one where you said we’d reach $10 in a few weeks is expired since it had already been a few weeks.

You want to bet on another timeline?

FNMA

ducci1 9 minutes ago

Pivot Calcs: SPX Pivot 5627----R1--5691----S1--5550-----SPY Pivot 561----R1--567----S1--554----ES Pivot 5643 !!LOL!!

SPY

weedtrader420 11 minutes ago

XRP 🏰 😂👍🍀 another good old post

XRPUSD

Bull_Dolphin 11 minutes ago

Kunstler:

The Glow of the Gaslight
"There’s a chance to restore democracy from the bureaucracy, but just a chance." —Elon Musk

James Howard Kunstler
Mar 10, 2025
CBS 60-Minutes’ Gaslighter-in-Chief Scott Pelley was at it again Sunday night trying to

weedtrader420 21 minutes ago

🤔🫣😂👍

XRPUSD

Hoghead7 26 minutes ago

Yahoo most recent earnings update is a bit impressive. Only ($1.35) per share loss. That's gonna be tough. Should get the $36.27: Revenue
https://www.google.com/url?rct=j&sa=t&url=https://finance.yahoo.com/news/fuelcell-energy-fcel-q4-earnings-120132945.html&ct=ga&cd=CAEYAioTODE0MjI0NDg1M

FCEL

Seminole Red 30 minutes ago

good pickin Beerworld....

benhor 31 minutes ago

$STSS dollar land coming

STSS

mwab52 32 minutes ago

Good morning (RNVA-Land & Team).........🤑😎.........Go (RNVA)

RNVA

benhor 32 minutes ago

$STSS dollar land coming

STSS

benhor 32 minutes ago

$STSS dollar land coming

STSS

NYBob 33 minutes ago

PRAYERS THANKS - Trump Didn’t See This Coming: Canada to Blocking US Free Access to Alaska: 1.2M views ·
1.2M views · 15 hours ago.

https://1a-1791.com/video/fwe2/5b/s8/1/s/d/M/q/sdMqy.oq1b.2-small-Trump-Didnt-See-This-Coming.jpg

https://rumble.com/v6q

EBS NCI

archilles 34 minutes ago

Release coming soon with a stroke of a pen. Altman did not buy millions of FMCC for no reason.

FMCC

NYBob 35 minutes ago

MAGA NEWS - Trump Didn’t See This Coming: Canada to Blocking US Free Access to Alaska: 1.2M views ·
1.2M views · 15 hours ago.

https://1a-1791.com/video/fwe2/5b/s8/1/s/d/M/q/sdMqy.oq1b.2-small-Trump-Didnt-See-This-Coming.jpg

https://rumble.com/v6qbhsi-

EBS NCI

NYBob 38 minutes ago

STAR NEWS -Trump Didn’t See This Coming: Canada to Blocking US Free Access to Alaska: 1.2M views ·
1.2M views · 15 hours ago.

https://1a-1791.com/video/fwe2/5b/s8/1/s/d/M/q/sdMqy.oq1b.2-small-Trump-Didnt-See-This-Coming.jpg

https://rumble.com/v6qbhsi-t

EBS NCI

NYBob 41 minutes ago

Trump Didn’t See This Coming: Canada to Blocking US Free Access to Alaska: 1.2M views ·
1.2M views · 15 hours ago.

https://1a-1791.com/video/fwe2/5b/s8/1/s/d/M/q/sdMqy.oq1b.2-small-Trump-Didnt-See-This-Coming.jpg

https://rumble.com/v6qbhsi-trump-didnt-

EBS NCI

Truth and Transparency 46 minutes ago

Let’s be honest, Mark and Jim have an awful track record for maintaining shareholder value!

Ppastis 48 minutes ago

How does it feel when you know everything in advance ? You must have a lmade a lot of money ! ( but still on this board every day ??? Strange ? Non? ) Can you give me e few more things that will happen in the future ? I will be greatful the rest of my life !!

LWLG

MiamiGent 52 minutes ago

Info Wars reporter Jamie White has been murdered leaving work down in Austin Texas.
Laura Loomer betta get bodyguards.
She does tremendous investigative reporting, like just digging to find Reid Hoffman has contributed to groups funding the organization violently attacking Elon's store

eagle8 52 minutes ago

Wiz888999
@ODB123
🔥🚨 DTCC is officially in the HOT SEAT! 🚨🔥

Court orders them to hand over records on daily failures to deliver, clearing data, and all that behind-the-scenes broker magic.

The receipts are coming out, and so

NWBO

valleybenedetto 54 minutes ago

🤦🤦🤦

MRES

Vashi 54 minutes ago

Still Holding 21k Fnma.
Confused weather to sell or hold..Loosing.
Any advice.?

FNMA

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Alpha Cognition Inc (ACOG)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Ask ADVFN Intelligence (AI)

ACOG Latest News

FeaturedNorthstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Form 8-K - Current report

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Form POS AM - Post-Effective amendments for registration statement

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

Alpha Cognition Announces Partial Exercise of Over-allotment Option

FeaturedNorthstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Form 8-K - Current report

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Form POS AM - Post-Effective amendments for registration statement

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

ACOG - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Alpha Cognition Inc (ACOG) Quote

Alpha Cognition Inc (ACOG)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Ask ADVFN Intelligence (AI)

ACOG Latest News

FeaturedNorthstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Form 8-K - Current report

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Form POS AM - Post-Effective amendments for registration statement

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

Alpha Cognition Announces Partial Exercise of Over-allotment Option

FeaturedNorthstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Form 8-K - Current report

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Form POS AM - Post-Effective amendments for registration statement

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

ACOG - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Go Ad-Free